Belief BioMed obtains license to use Lonza’s AAV 5B8 Expression System in house
Belief BioMed has entered a new research license agreement to use Lonza’s AAV Xcite? AAV Platform. This includes the use of our 5B8 Expression System - a suspension expression system for AAV-based gene therapy that can be scaled up for production. We’re delighted to be working with Dr. Jane Zheng and the Belief BioMed team and look forward to seeing what they go on to achieve as a result of the collaboration!
Find out how to get Lonza’s 5B8 expression system in your lab: https://www.lonza.com/knowledge-center/cellgene/w/helper-repcap-plasmids-aav-productivity
Associate Director Licensing at Lonza
1 年Great news! Scalability is key for the success of gene therapy. Thanks for sharing!
Biotech Licensing Expert @ Lonza | Accelerating Therapies to Patients
1 年Great job Ulrich Osswald and Lucien Zhang and thank you for sharing.